GlaxoSmithKline is recalling Lot A21CB242A of the Infanrix Hexa vaccine, which is offered only through vaccination programs in British Columbia and the Yukon, Health Canada said Friday.
No contamination has been found in the vaccine, said GSK, and the recall is a precautionary measure only.
Infanrix Hexa is used to protect children against diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type B diseases.
A search of the GSK worldwide safety database found no reported adverse events potentially linked to the contamination, said Health Canada, noting the company has sent letters to health-care professionals informing them of the recall.
Consumers who have questions or require additional information regarding the use of Infanrix Hexa should contact their medical practitioner.
Any cases of serious or unexpected adverse events in patients receiving Infanrix Hexa should be reported to GSK by calling toll-free 1-800-387-7374 or by contacting the local health department.